Chemed Corporation $CHE Stock Sold by Signal Advisors Wealth LLC

Key Points

• Signal Advisors Wealth reduced its Chemed stake by 13.9% in the third quarter, selling 2,852 shares and retaining 17,713 shares worth approximately $8.95 million. Institutional investors collectively own 95.85% of Chemed.
• Chemed reported quarterly revenue of $673.25 million and earnings of $6.06 per share, exceeding analyst estimates, while revenue increased 8.8% year over year. Shares opened at $501.18, with a consensus analyst rating of “Hold” and an average price target of $554.60.
• The company raised its quarterly dividend to $0.70 per share, up from $0.60, equivalent to an annualized dividend of $2.80 and a 0.6% yield. Company insiders, including the CEO and an executive vice president, have sold shares recently.

Signal Advisors Wealth LLC reduced its position in Chemed Corporation (NYSE:CHE - Free Report) by 13.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,713 shares of the company's stock after selling 2,852 shares during the period. Signal Advisors Wealth LLC owned 0.14% of Chemed worth $8,946,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Copeland Capital Management LLC grew its holdings in Chemed by 1.3% during the 3rd quarter. Copeland Capital Management LLC now owns 146,833 shares of the company's stock valued at $74,162,000 after buying an additional 1,826 shares in the last quarter. GAMMA Investing LLC increased its stake in Chemed by 7.3% in the 3rd quarter. GAMMA Investing LLC now owns 665 shares of the company's stock worth $336,000 after acquiring an additional 45 shares during the last quarter. Farther Finance Advisors LLC increased its stake in Chemed by 25.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,161 shares of the company's stock worth $587,000 after acquiring an additional 239 shares during the last quarter. Fenimore Asset Management Inc increased its stake in Chemed by 0.3% in the 3rd quarter. Fenimore Asset Management Inc now owns 36,631 shares of the company's stock worth $18,501,000 after acquiring an additional 103 shares during the last quarter. Finally, Sequoia Financial Advisors LLC bought a new stake in Chemed in the 2nd quarter worth approximately $563,000. 95.85% of the stock is owned by institutional investors.

Chemed Stock Up 0.1%

Shares of NYSE:CHE opened at $501.18 on Wednesday. The company has a market cap of $6.55 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 2.01 and a beta of 0.51. Chemed Corporation has a 12 month low of $365.20 and a 12 month high of $557.00. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17. The company has a 50-day moving average price of $519.71 and a 200 day moving average price of $468.79.

Chemed (NYSE:CHE - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, topping the consensus estimate of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%. The company had revenue of $673.25 million for the quarter, compared to analysts' expectations of $665.04 million. During the same period in the previous year, the firm posted $4.27 earnings per share. The firm's revenue for the quarter was up 8.8% on a year-over-year basis. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. As a group, equities research analysts predict that Chemed Corporation will post 23.55 earnings per share for the current year.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 0.6%. This is a positive change from Chemed's previous quarterly dividend of $0.60. The ex-dividend date was Monday, August 17th. Chemed's dividend payout ratio (DPR) is presently 14.06%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CHE shares. Oppenheimer increased their target price on Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Royal Bank Of Canada raised their target price on shares of Chemed from $436.00 to $548.00 and gave the company a "sector perform" rating in a report on Thursday, July 30th. Bank of America restated a "neutral" rating on shares of Chemed in a research report on Wednesday, July 29th. Wall Street Zen raised shares of Chemed from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, UBS Group assumed coverage on shares of Chemed in a research note on Friday, September 25th. They set a "buy" rating and a $650.00 price target on the stock. Two research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, Chemed currently has a consensus rating of "Hold" and a consensus price target of $554.60.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $539.51, for a total value of $1,079,020.00. Following the completion of the sale, the chief executive officer owned 70,418 shares in the company, valued at approximately $37,991,215.18. This trade represents a 2.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Spencer S. Lee sold 1,000 shares of Chemed stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the transaction, the executive vice president directly owned 13,912 shares of the company's stock, valued at approximately $7,526,948.48. This represents a 6.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 9,190 shares of company stock worth $4,833,160 over the last quarter. Insiders own 3.33% of the company's stock.

Chemed Profile

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.